PORT Can Improve Survival for Non-Small Cell Lung Cancer (NSCLC) Patients
the Cancer Therapy Advisor take:
According to new findings presented at the 2014 Multidisciplinary Symposium in Thoracic Oncology in Chicago, Illinois, researchers have found that patients who underwent post-operative radiation therapy (PORT) survived 4 months longer, on average, compared with patients with similar cancer characteristics who did not receive PORT.
For the study, researchers identified 2,115 patients with non-small cell lung cancer (NSCLC) from the National Cancer Data Base. In order to be included, patients had to have had surgically removed NSCLC with N2 lymph node involvement and received chemotherapy. Of those, 43% underwent PORT while nearly 57% did not.
Results showed that patients who received PORT had a median survival time of 42 months compared with 38 months among patients not treated with PORT (P = 0.048). Factors associated with improved overall survival were 1-2 involved lymph nodes, adenocarcinoma histology, female age, higher income, being from a rural or urban setting, and younger age.
The findings suggest the importance of PORT for patients with NSCLC with involved mediastinal lymph nodes as it can improve overall survival by about 4 months. Researchers recommend that PORT be considered in addition to chemotherapy following removal of NSCLC.
Patients who underwent post-operative radiation therapy for NSCLC survived longer.
Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago Medicine.
This study reviewed the records of non-small cell lung cancer patients treated from 2004 to 2006 from the National Cancer Data Base (NCDB), a joint endeavour of the Commission on Cancer of the American College of Surgeons and the American Cancer Society.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer